• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    22nd Century Group Reports Third Quarter 2024 Financial Results

    11/12/24 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $XXII alert in real time by email

    Remains on Path to Cash Positive Operations in Q1 2025

    Commencing Growth Strategy Leveraging Both Internal and External Brand Assets Across Multiple Categories

    Mocksville, North Carolina--(Newsfile Corp. - November 12, 2024) - 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announced results for the third quarter ended September 30, 2024, and provided an update on recent business highlights.

    Third Quarter 2024 Financial Results (compared to Second Quarter 2024, except as noted)

    All figures reported below reflect continuing operations, excluding discontinued operations related to the sale and exit of the Company's hemp/cannabis business in late 2023.

    • Net revenues decreased sequentially to $5.9 million, compared to $7.9 million.
    • Gross profit was $(0.6) million, compared to $0.6 million.
    • Operating loss increased to $3.4 million, compared to $2.0 million.
    • Net loss increased to $3.6 million, compared to $2.2 million.
    • Basic and diluted EPS decreased to $(0.27), compared to $(0.30).
    • Adjusted EBITDA loss increased to $3.2 million, from a loss of $2.6 million.
    • Net debt improved to $3.0 million, compared to $7.0 million in the preceding quarter of 2024.

    "Having joined this company just under a year ago, we have transitioned from a purely financial focus to the next phase of 22nd Century Group's turnaround plans, which includes deploying our extensive asset base of manufacturing, brand, customer relationship and distribution resources to build a sustainable and self-funding growth business," said Larry Firestone, Chairman and CEO. "While the third quarter results reflect the operational adjustments that I spoke to on our last report intended to address underperforming results in the filtered cigar business, we remain focused on our goal of EBITDA breakeven results in the first quarter of 2025. We expect that the changes in our core CMO business will drive revenue growth going forward at appropriate margin levels.

    "I am also excited to announce that we are now moving ahead on our plans to launch additional products, including VLN® SKUs within key customer brand families, as part of our drive to expand the distribution of reduced nicotine content cigarettes manufactured by 22nd Century. Adding VLN® within other brand families is a straightforward way to reduce our time to market, increase consumer awareness and expand the VLN® footprint. This is really the beginning for 22nd Century as the synchronicity between the CMO business and VLN® is progressing as planned and is the foundation for our growth plans for 2025 and beyond."

    Third Quarter 2024 - Discussion of Product Line Net Revenues

    • Cigarette net revenues, including export volume, increased to $4.1 million or 18% compared to $3.5 million in the prior year comparable period. Q3 2024 cigarette carton volumes declined 22% due to prior year comparable period stocking orders but benefitted from price increases that took effect in April 2024. Cigarette net revenues were stable compared to the immediately preceding quarter, which benefitted from a periodic Spectrum® research cigarette order valued at $0.9 million.

    • Filtered cigars net revenues decreased to $1.7 million, compared to $4.1 million in the prior year comparable period, and $3.3 million in the immediately preceding quarter, reflecting lower volumes as the Company completed last time buy orders under our terminated contract manufacturing agreements, now having transitioned away from low or negative margin filtered cigar orders. Additionally, price increases for certain customers took effect in April 2024. The Company is presently in discussions for additional volume in this category under new agreements with improved margin.

    • Cigarillo distribution net revenues amounted to $0.2 million, compared to $0 in the prior year quarter and $0.6 million in the preceding quarter, reflective of the expanded Pinnacle branded product offerings launched in Q2 2024 with a top-five national convenience store chain.

    • VLN® cigarette net revenues were negligible in the third quarter, a decrease from the comparable prior year period which benefited from stocking orders with major c-stores. While the Company has secured broad distribution of its VLN® products, the sell-through has not yet materialized. The Company is making changes to rebrand and relaunch its VLN® products, which will be discussed further on the conference call noted below.

    Conference Call

    22nd Century will host a live webcast today at 8:00 a.m. E.T. to discuss its third quarter 2024 financial results and business highlights. The live and archived webcast will be accessible in the Events section on 22nd Century's Investor Relations website at https://ir.xxiicentury.com/events.

    Summary Financial Results
    (dollars in thousands, except per share data)

    Three Months Ended
    September 30, Change
    20242023$%
    Revenues, net$5,946$7,871(1,925)(24.5)
    Gross profit (loss)$(588)$77(665)(863.6)
    Operating loss$(3,377)$(8,253)4,876(59.1)
    Net loss from continuing operations$(3,585)$(8,081)4,496(55.6)
    Basic and diluted loss per common share from continuing operations$(0.27)$(6.70)6(96.0)
    Adjusted EBITDA (a)$(3,178)$(6,528)3,35051.3

     

    Nine Months Ended
    September 30, Change
    20242023$%
    Revenues, net$20,361$24,848(4,487)(18.1)
    Gross profit (loss)$(1,147)$(867)(280)32.3
    Operating loss$(9,858)$(30,699)20,841(67.9)
    Net loss from continuing operations$(11,248)$(32,618)21,370(65.5)
    Basic and diluted loss per common share from continuing operations$(1.35)$(33.35)32(96.0)
    Adjusted EBITDA (a)$(9,247)$(25,740)16,49364.1


    (a) Adjusted EBITDA is a non-GAAP financial measure. Please see "Notes Regarding Non-GAAP Financial Information" for additional information regarding our use of non-GAAP financial measures. Refer to Tables A at the end of this release for reconciliations of adjusted amounts to the closest corresponding GAAP financial measures.

    Summary Product Line Results
    (in thousands)

    Three Months Ended
    September 30,
    20242023Change
    $Cartons$Cartons$Cartons
    Contract Manufacturing
      Cigarettes4,0781563,463200615(44)
      Filtered Cigars1,6642534,088621(2,424)(368)
      Cigarillos20430--20430
       Total Contract Manufacturing5,9464397,551821(1,605)(382)
      VLN®--3206(320)(6)
       Total Product Line Revenues5,9464397,871827(1,925)(388)
          

     

    Nine Months Ended
    September 30,
    20242023Change
    $Cartons$Cartons$Cartons
    Contract Manufacturing
      Cigarettes10,94241611,735640(793)(224)
      Filtered Cigars8,5931,24912,4141,937(3,821)(688)
      Cigarillos756120--756120
       Total Contract Manufacturing20,2911,78524,1492,577(3,858)(792)
      VLN®70169914(629)(13)
       Total Product Line Revenues20,3611,78624,8482,591(4,487)(806)

     

    About 22nd Century Group, Inc.

    22nd Century Group is the pioneering nicotine harm reduction company in the tobacco industry enabling smokers to take control of their nicotine consumption.

    We created our flagship product, the VLN® cigarette, to give traditional cigarette smokers an authentic and familiar alternative that helps them take control of their nicotine consumption. VLN® cigarettes have 95% less nicotine than the traditional cigarette and have been proven to greatly reduce nicotine consumption. Instead of offering new ways of delivering nicotine to addicted smokers, we offer smokers the option to take control of their nicotine consumption and make informed and more productive choices, including the choice to avoid addictive levels of nicotine altogether.

    Our wholly owned subsidiaries include a leading cigarette manufacturer that produces all VLN® products and provides turnkey contract manufacturing for other tobacco brands both domestically and internationally. The 60,000 square foot facility in Mocksville, North Carolina has the capacity to produce more than 45 million cartons of combusted tobacco products annually with additional space for expansion.

    Our proprietary reduced nicotine tobacco blends are made possible by comprehensive and patented technologies that regulate nicotine biosynthesis activities in the tobacco plant, resulting in full flavor and high yield with 95% less nicotine. Our extensive patent portfolio has been developed to ensure we have the only low nicotine combustible cigarette in the United States and critical international markets. Our mission is to sell the last cigarette before the 22nd Century.

    VLN® and Helps You Smoke Less® are registered trademarks of 22nd Century Limited LLC.

    Learn more at xxiicentury.com, on X (formerly Twitter), on LinkedIn, and on YouTube.

    Learn more about VLN® at tryvln.com.

    Cautionary Note Regarding Forward-Looking Statements

    Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "explore," "foresee," "goal," "guidance," "intend," "likely," "may," "plan," "potential," "predict," "preliminary," "probable," "project," "promising," "seek," "should," "will," "would," and similar expressions. Forward-looking statements include, but are not limited to, statements regarding (i) our cost reduction initiatives, (ii) our expectations regarding regulatory enforcement, including our ability to receive an exemption from new regulations, (iii) our financial and operating performance and (iv) our expectations for our business interruption insurance claim. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in "Risk Factors" in the Company's Annual Report on Form 10-K filed on March 28, 2024, and in the Company's Quarterly Reports filed on May 15, 2024 and August 13, 2024. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

    Notes regarding Non-GAAP Financial Information

    In addition to the Company's reported results in accordance with generally accepted accounting principles in the United States of America ("GAAP"), the Company provides EBITDA and Adjusted EBITDA.

    In order to calculate EBITDA, the Company adjusts net (loss) income by adding back interest expense (income), provision (benefit) for income taxes, and depreciation and amortization expense. Adjusted EBITDA consists of EBITDA adjusted by the Company for certain non-cash and/or non-operating expenses, including adding back equity-based employee compensation expense, restructuring and restructuring-related charges such as impairment, acquisition and transaction costs, and other unusual or infrequently occurring items, if applicable, such as inventory reserves and adjustments, gains or losses on disposal of property, plant and equipment, and gains or losses on investments.

    The Company believes that the presentation of EBITDA and Adjusted EBITDA are important financial measures that supplement discussion and analysis of its financial condition and results of operations and enhances an understanding of its operating performance. While management considers EBITDA and Adjusted EBITDA to be important, these financial performance measures should be considered in addition to, but not as a substitute for or superior to, other measures of financial performance prepared in accordance with GAAP, such as operating (loss) income, net (loss) income and cash flows from operations. Adjusted EBITDA is susceptible to varying calculations and the Company's measurement of Adjusted EBITDA may not be comparable to those of other companies.

    Net total debt is calculated as total principal amount of debt outstanding less cash and cash equivalents. In addition to the performance measures identified above, we believe that net total debt provides a meaningful measure of liquidity and a useful basis for assessing our ability to fund our activities, including the financing of scheduled debt repayments.

    Investor Relations & Media Contact
    Matt Kreps
    Investor Relations
    22nd Century Group
    [email protected]
    214-597-8200

    22nd CENTURY GROUP, INC.
    CONDENSED CONSOLIDATED BALANCE SHEETS
    (Unaudited)
    (amounts in thousands, except share and per-share data)

    September 30, December 31,
    20242023
    ASSETS
     Current assets:
       Cash and cash equivalents$5,341$2,058
       Accounts receivable, net1,7841,671
       Inventories2,3404,346
       Insurance recoveries3,7683,768
       GVB promissory note5002,000
       Prepaid expenses and other current assets9791,180
       Current assets of discontinued operations held for sale1,0511,254
         Total current assets15,76316,277
       Property, plant and equipment, net2,9703,393
       Operating lease right-of-use assets, net1,7051,894
       Intangible assets, net5,7255,924
       Other assets1515
    Total assets$26,178$27,503
      
    LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)  
     Current liabilities:  
       Notes and loans payable - current$569$543
       Current portion of long-term debt1,5005,848
       Operating lease obligations252231
       Accounts payable 3,0984,445
       Accrued expenses1,3671,322
       Accrued litigation3,7683,768
       Accrued payroll183883
       Accrued excise taxes and fees2,1592,234
       Deferred income54726
       Other current liabilities1941,849
       Current liabilities of discontinued operations held for sale1,2953,185
         Total current liabilities14,43925,034
     Long-term liabilities:  
       Operating lease obligations1,5061,698
       Long-term debt5,5298,058
       Other long-term liabilities1,2321,123
    Total liabilities22,70635,913
    Shareholders' equity (deficit)  
          Preferred stock, $.00001 par value, 10,000,000 shares authorized  
          Common stock, $.00001 par value, 250,000,000 shares authorized  
       Capital stock issued and outstanding:  
          29,378,321 common shares (2,720,437 at December 31, 2023)  
       Common stock, par value--
       Capital in excess of par value392,787370,297
       Accumulated deficit(389,315)(378,707)
    Total shareholders' equity (deficit)3,472(8,410)
    Total liabilities and shareholders' equity (deficit)$26,178$27,503

     

    22nd CENTURY GROUP, INC.
    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
    (Unaudited)
    (amounts in thousands, except share and per-share data)

    Three Months EndedNine Months Ended
    September 30, September 30,
    2024202320242023
    Revenues, net$5,946$7,871$20,361$24,848
    Cost of goods sold3,1023,92111,18413,327
    Excise taxes and fees on products3,4323,87310,32412,388
    Gross (loss) profit(588)77(1,147)(867)
    Operating expenses:    
       Sales, general and administrative2,5476,9397,81427,058
       Research and development2406239152,152
       Other operating expense (income), net2768(18)622
         Total operating expenses2,7898,3308,71129,832
    Operating loss from continuing operations(3,377)(8,253)(9,858)(30,699)
    Other income (expense):    
       Other income (expense), net1001,272439504
       Interest income, net37926201
       Interest expense(311)(1,179)(1,828)(2,578)
         Total other income (expense)(208)172(1,363)(1,873)
    Loss from continuing operations before income taxes(3,585)(8,081)(11,221)(32,572)
    Provision for income taxes--2746
    Net loss from continuing operations$(3,585)$(8,081)$(11,248)$(32,618)
        
    Discontinued operations:    
    Income (loss) from discontinued operations before income taxes$(172)$(64,639)$640$(78,823)
    Provision for income taxes----
    Net income (loss) from discontinued operations$(172)$(64,639)$640$(78,823)
        
    Net loss$(3,757)$(72,720)$(10,608)$(111,441)
    Deemed dividends(3,677)(564)(7,711)(931)
    Net loss available to common shareholders$(7,434)$(73,284)$(18,319)$(112,372)
        
    Basic and diluted loss per common share from continuing operations$(0.27)$(6.70)$(1.35)$(33.35)
    Basic and diluted loss per common share from discontinued operations$(0.01)$(53.58)$0.08$(80.58)
    Basic and diluted loss per common share from deemed dividends$(0.27)$(0.47)$(0.93)$(0.95)
    Basic and diluted loss per common share$(0.55)$(60.75)$(2.20)$(114.88)
    Weighted average common shares outstanding - basic and diluted13,507,4411,206,3688,316,768978,168
        
        
    Net loss$(3,757)$(72,720)$(10,608)$(111,441)
    Other comprehensive income:    
    Unrealized gain on short-term investment securities---71
    Foreign currency translation-(69)-(31)
    Reclassification of realized losses to net loss---41
    Other comprehensive income-(69)-81
    Comprehensive loss$(3,757)$(72,789)$(10,608)$(111,360)

     

    Table A - Reconciliations of Non-GAAP Measures
    (dollars in thousands, except share and per-share data)

    Below is a table containing information relating to the Company's Net loss, EBITDA and Adjusted EBITDA for the three and nine month periods ended September 30, 2024 and 2023, including a reconciliation of these Non-GAAP measures for such periods.

    Quarter Ended
    September 30,
    Amounts in thousands ($000's)
    except share and per share data
    (UNAUDITED)
    $ Change
    20242023fav / (unfav)1
    Net loss from continuing operations$ (3,585)$ (8,081)$ 4,496
    Interest (income)/expense, net3081,100(792)
    Provision (benefit) for income taxes---
    Amortization and depreciation249411(162)
    EBITDA$(3,028)$(6,570)$3,542
    Adjustments:   
    Restructuring and impairment(23)545(568)
    Change in fair value of derivative liabilities(23)-(23)
    Change in fair value of warrant liabilities(100)(1,263)1,163
    Equity-based employee compensation expense(4)538(542)
    Adjusted EBITDA$(3,178)$(6,528)$3,350
       
    Adjusted EBITDA loss per common share$(0.24)$(5.41)$5.18
    Weighted average common shares outstanding - basic and diluted13,507,4411,206,368 

     

    Year Ended
    September 30,
    Amounts in thousands ($000's)
    except share and per share data
    (UNAUDITED)
    $ Change
    20242023fav / (unfav)1
    Net loss from continuing operations$ (11,248)$ (32,618)$ 21,370
    Interest (income)/expense, net1,8022,377(575)
    Provision (benefit) for income taxes2746(19)
    Amortization and depreciation7621,137(375)
    EBITDA$(8,657)$(29,058)$20,401
    Adjustments:   
    Restructuring and impairment(348)545(893)
    Inventory write-down431-431
    Change in fair value of derivative liabilities(482)-(482)
    Change in fair value of warrant liabilities(424)(540)116
    Equity-based employee compensation expense2333,091(2,858)
    Adjusted EBITDA$(9,247)$(25,740)$16,493
       
    Adjusted EBITDA loss per common share$(0.00)$(0.03)$0.03
    Weighted average common shares outstanding - basic and diluted8,316,768978,168 

     

    1Fav = Favorable variance, which increases EBITDA and Adjusted EBITDA; Unfav = unfavorable variance, which reduces EBITDA and Adjusted EBITDA

    Table B: Net Total Debt Reconciliation
    (dollars in thousands)

    September 30, December 31,
    20242023
    Total debt$ 7,029$ 13,906
    Add: debt discounts and deferred issuance costs included in total debt1,2921,453
    Total principal amount of debt outstanding8,32115,359
    Less: Cash and cash equivalents5,3412,058
    Net total debt (Non-GAAP)$2,980$13,301

     

    Corporate Logo

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/229484

    Get the next $XXII alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XXII

    DatePrice TargetRatingAnalyst
    7/21/2022$5.00Buy
    Alliance Global Partners
    6/15/2022$5.00Buy
    Craig Hallum
    3/8/2022$6.00Buy
    Roth Capital
    7/23/2021$5.00Outperform
    Cowen
    More analyst ratings

    $XXII
    Financials

    Live finance-specific insights

    See more
    • 22nd Century Group Reports First Quarter 2025 Financial Results

      Sales Increase Approximately 50% Sequentially as 2025 Growth Strategy Drives New Sales Activity with Both Internal and External Brand Assets Across Multiple Categories  Preparing First VLN® Partner Brand Shipments with Smoker Friendly and Others Filings Made for New Reduced Nicotine Content and Conventional Product Authorizations in All 50 States Launch of Smoker Friendly Black Label – Tobacco and Water natural style cigarettes MOCKSVILLE, N.C., May 13, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announ

      5/13/25 6:00:00 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • 22nd Century Group Completes Sale of Needle Rock Farms Assets

      Further Strengthens Balance Sheet Cash Position MOCKSVILLE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announced closing of the sale of its Needle Rock Farms assets with net proceeds of approximately $770,000 after expenses. "The sale of unused assets such as Needle Rock Farms which was related to the hemp cannabis business that was sold in December 2023, enables us to redeploy capital into our current growth plans," said Larry Firestone, CEO of 22nd Century Group. "The additional $770,000 in

      5/8/25 5:07:00 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • 22nd Century Group Further Reduces Debt by $1.0 Million Following Financing Transaction

      Year to Date Total Debt Reduction of approximately $3.8 Million MOCKSVILLE, N.C., May 07, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announced that has repaid an additional $1 million in debt to its senior lender. The Company's total debt principal outstanding now stands at approximately $3.9 million. "Our debt reduction progress has been outstanding and total debt principal is now less than $4 million, as compared with approximately $20 million of total debt obligations when I joined the Company in Decemb

      5/7/25 8:00:00 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Firestone Lawrence bought $10,468 worth of shares (39,000 units at $0.27), increasing direct ownership by 256% to 54,250 units (SEC Form 4)

      4 - 22nd Century Group, Inc. (0001347858) (Issuer)

      9/12/24 5:00:14 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Firestone Lawrence bought $9,829 worth of shares (9,000 units at $1.09), increasing direct ownership by 144% to 15,250 units (SEC Form 4)

      4 - 22nd Century Group, Inc. (0001347858) (Issuer)

      5/31/24 4:05:20 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Arno Andrew bought $17,490 worth of shares (100,000 units at $0.17) (SEC Form 4)

      4 - 22nd Century Group, Inc. (0001347858) (Issuer)

      1/8/24 8:04:11 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    Leadership Updates

    Live Leadership Updates

    See more
    • 22nd Century Announces Resignation of John Miller as President of Tobacco

      Helped Establish National Scale Distribution and Launch VLN in More Than 5,000 Stores Across the CountryMocksville, North Carolina--(Newsfile Corp. - May 30, 2024) - 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on nicotine harm reduction, today announced that John Miller has resigned as President of Tobacco, effective August 2, 2024. Said Larry Firestone, Chairman and CEO: "I want to thank John for the pivotal role he played in the launch of VLN®, leveraging his decades of industry experience to help us achieve national-scale distribution and establishing a retail presence in more than 5,000 stores across 26 states. He also played a key role in expanding our CMO

      5/30/24 4:05:00 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • 22nd Century Group (Nasdaq: XXII) Appoints Accomplished Media Executive Lucille S. Salhany to Its Board

      BUFFALO, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced the appointment of Lucie S. Salhany to its Board of Directors. Ms. Salhany is a highly accomplished media executive with extensive experience in assessing and understanding the consumer landscape, positioning unique products for successful launch utilizing digital media, corporate strategy, and entrepreneurial ventures. She is widely recognized for her appointment as the first woman chair of a major broadcast network, which was e

      9/12/22 4:05:00 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • 22nd Century Group (Nasdaq: XXII) Appoints R. Hugh Kinsman as CFO

      CFO of GVB Biopharma to Expand Role, Become CFO of 22nd Century GroupIntegration of GVB Biopharma Proceeding at a Rapid Pace BUFFALO, N.Y., June 16, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company), dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technology, today announced the appointment of R. Hugh Kinsman as Chief Financial Officer. Kinsman is currently CFO of GVB Biopharma, which 22nd Century acquired effective May 13, 2022. "The integration of GVB Biopharma is proceeding very well, and we are excited to build on Hugh's success at GVB by elevating his financial lea

      6/16/22 8:30:00 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream

      MIAMI, May 21, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting Today, May 21, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go ba

      5/21/25 7:00:00 AM ET
      $ASPI
      $ATCH
      $CIA
      $CLNN
      Major Chemicals
      Industrials
      Finance: Consumer Services
      Finance
    • Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream

      MIAMI, May 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1May 21, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go back to the

      5/20/25 7:00:00 AM ET
      $ASPI
      $ATCH
      $CIA
      $CLNN
      Major Chemicals
      Industrials
      Finance: Consumer Services
      Finance
    • 22nd Century to Present at the Emerging Growth Conference on May 21, 2025

      MOCKSVILLE, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine and believes smokers should have a choice about their nicotine consumption, (the "Company") is pleased to announce that Larry Firestone, Chief Executive Officer, will present a brief corporate update at the Emerging Growth Conference on Wednesday, May 21, 2025, at 12:00 pm Eastern Time. Mr. Firestone will provide updates to recent company advancements and may subsequently open the floor for questions. Questions may be submitted in advance to [email protected]. Investors can register in advance to attend the conference

      5/19/25 4:15:00 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    SEC Filings

    See more

    $XXII
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form EFFECT filed by 22nd Century Group Inc.

      EFFECT - 22nd Century Group, Inc. (0001347858) (Filer)

      5/23/25 12:15:08 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form PRE 14A filed by 22nd Century Group Inc.

      PRE 14A - 22nd Century Group, Inc. (0001347858) (Filer)

      5/22/25 4:45:37 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • 22nd Century Group Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - 22nd Century Group, Inc. (0001347858) (Filer)

      5/22/25 4:30:26 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Alliance Global Partners initiated coverage on 22nd Century Group with a new price target

      Alliance Global Partners initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $5.00

      7/21/22 9:12:19 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Craig Hallum initiated coverage on 22nd Century Group with a new price target

      Craig Hallum initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $5.00

      6/15/22 7:42:24 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Roth Capital initiated coverage on 22nd Century Group with a new price target

      Roth Capital initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $6.00

      3/8/22 9:21:23 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

      SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

      12/3/24 11:18:54 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

      SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

      11/14/24 5:56:57 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by 22nd Century Group Inc.

      SC 13G - 22nd Century Group, Inc. (0001347858) (Subject)

      10/23/24 7:27:00 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Johnson Anthony L. was granted 2,472 shares, increasing direct ownership by 35,314% to 2,479 units (SEC Form 4)

      4 - 22nd Century Group, Inc. (0001347858) (Issuer)

      3/12/25 5:37:14 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Salhany Lucille S was granted 2,472 shares, increasing direct ownership by 49,440% to 2,477 units (SEC Form 4)

      4 - 22nd Century Group, Inc. (0001347858) (Issuer)

      3/12/25 5:35:14 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Arno Andrew was granted 4,237 shares, increasing direct ownership by 9,015% to 4,284 units (SEC Form 4)

      4 - 22nd Century Group, Inc. (0001347858) (Issuer)

      3/12/25 5:30:19 PM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care

    $XXII
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

      For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

      12/23/21 9:06:12 AM ET
      $XXII
      Medicinal Chemicals and Botanical Products
      Health Care